{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T06:03:16Z","timestamp":1789797796232,"version":"4.0.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":53,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Acquired endocrine resistance in ER\n                    <jats:sup>+<\/jats:sup>\n                    breast cancer (BC) involves metabolic reprogramming, yet key drivers are unclear. Multi-omics of endocrine-resistant BC revealed upregulated oxidative phosphorylation (OXPHOS) and identified intercellular adhesion molecule 2 (ICAM2) as a biomarker of high-OXPHOS cells. ICAM2-positive cells were significantly enriched in resistant tumors and predicted poor survival, and were functionally essential for maintaining resistance and promoting metastasis in vivo. Mechanistically, ICAM2 binds dynein light chain DYNLT3 and the mitochondrial complex I subunit MT-ND2, thereby facilitating dynein-mediated mitochondrial trafficking and further modulating the assembly of mitochondrial complex I. Disrupting this interaction through ICAM2 knockdown or dynein inhibition (Ciliobrevin D) effectively suppressed OXPHOS activity. Importantly, ER\u03b1 inhibition alleviates the transcriptional repression of ICAM2 by ER\u03b1. Therapeutically, combining the complex I inhibitor IACS-10759 with fulvestrant potently inhibited both tumor growth and metastasis. Collectively, these findings reveal that ICAM2 drives endocrine resistance via dynein-dependent OXPHOS activation, revealing a targetable axis in refractory ER\n                    <jats:sup>+<\/jats:sup>\n                    BC.\n                  <\/jats:p>","DOI":"10.1038\/s41419-026-08864-1","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T14:02:50Z","timestamp":1779112970000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["ICAM2 promotes endocrine resistance via dynein-mediated OXPHOS activation in ER-positive breast cancer"],"prefix":"10.1038","volume":"17","author":[{"given":"Si","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajie","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bohan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyue","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fen","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqing","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinqing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoliang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6947-1706","authenticated-orcid":false,"given":"Cuixia","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"key":"8864_CR1","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA: Cancer J Clin. 2025;75:10\u201345.","journal-title":"CA: Cancer J Clin"},{"key":"8864_CR2","doi-asserted-by":"crossref","unstructured":"Ferrari P, Schiavone ML, Scatena C, Nicolini A. Molecular mechanisms and therapeutic strategies to overcome resistance to endocrine therapy and CDK4\/6 inhibitors in advanced ER+\/HER2- breast cancer. Int J Mol Sci 2025;26:3438.","DOI":"10.3390\/ijms26073438"},{"key":"8864_CR3","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1016\/S0140-6736(20)32381-3","volume":"397","author":"S Loibl","year":"2021","unstructured":"Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G. Breast cancer. Lancet. 2021;397:1750\u201369.","journal-title":"Lancet"},{"key":"8864_CR4","first-page":"480","volume":"73","author":"LA Huppert","year":"2023","unstructured":"Huppert LA, Gumusay O, Idossa D, Rugo HS. Systemic therapy for hormone receptor-positive\/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer. CA: Cancer J Clin. 2023;73:480\u2013515.","journal-title":"CA: Cancer J Clin"},{"key":"8864_CR5","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","volume":"377","author":"H Pan","year":"2017","unstructured":"Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377:1836\u201346.","journal-title":"N Engl J Med"},{"key":"8864_CR6","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1158\/0008-5472.CAN-22-3059","volume":"83","author":"Z Lin","year":"2023","unstructured":"Lin Z, Li J, Zhang J, Feng W, Lu J, Ma X, et al. Metabolic reprogramming driven by IGF2BP3 promotes acquired resistance to EGFR inhibitors in non-small cell lung cancer. Cancer Res. 2023;83:2187\u2013207.","journal-title":"Cancer Res"},{"key":"8864_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202408599","volume":"12","author":"M Deng","year":"2024","unstructured":"Deng M, Zhou Z, Chen J, Li X, Liu Z, Ye J, et al. Enhanced oxidative phosphorylation driven by TACO1 mitochondrial translocation promotes stemness and cisplatin resistance in bladder cancer. Adv Sci. 2024;12:e2408599.","journal-title":"Adv Sci"},{"key":"8864_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2020.100143","volume":"1","author":"R Masoud","year":"2020","unstructured":"Masoud R, Reyes-Castellanos G, Lac S, Garcia J, Dou S, Shintu L, et al. Targeting mitochondrial Complex I overcomes chemoresistance in high OXPHOS Pancreatic Cancer. Cell Rep Med. 2020;1:100143.","journal-title":"Cell Rep Med"},{"key":"8864_CR9","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1182\/blood.2023020142","volume":"142","author":"Y Liu","year":"2023","unstructured":"Liu Y, Kimpara S, Hoang NM, Daenthanasanmak A, Li Y, Lu L, et al. EGR1-mediated metabolic reprogramming to oxidative phosphorylation contributes to ibrutinib resistance in B-cell lymphoma. Blood. 2023;142:1879\u201394.","journal-title":"Blood"},{"key":"8864_CR10","doi-asserted-by":"crossref","unstructured":"Chen D, Barsoumian HB, Fischer G, Yang L, Verma V, Younes AI, et al. Combination treatment with radiotherapy and a novel oxidative phosphorylation inhibitor overcomes PD-1 resistance and enhances antitumor immunity. J Immunother Cancer 2020;8:e000289.","DOI":"10.1136\/jitc-2019-000289"},{"key":"8864_CR11","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/s41573-025-01227-z","volume":"24","author":"MP Trefny","year":"2025","unstructured":"Trefny MP, Kroemer G, Zitvogel L, Kobold S. Metabolites as agents and targets for cancer immunotherapy. Nat Rev Drug Discov. 2025;24:764\u201384.","journal-title":"Nat Rev Drug Discov"},{"key":"8864_CR12","doi-asserted-by":"publisher","first-page":"5572","DOI":"10.1158\/0008-5472.CAN-20-3242","volume":"81","author":"KW Evans","year":"2021","unstructured":"Evans KW, Yuca E, Scott SS, Zhao M, Paez Arango N, Cruz Pico CX, et al. Oxidative phosphorylation is a metabolic vulnerability in chemotherapy-resistant triple-negative breast cancer. Cancer Res. 2021;81:5572\u201381.","journal-title":"Cancer Res"},{"key":"8864_CR13","doi-asserted-by":"crossref","unstructured":"Gong Y, Ji P, Yang YS, Xie S, Yu TJ, Xiao Y, et al. Metabolic-pathway-based subtyping of triple-negative breast cancer reveals potential therapeutic targets. Cell Metab 2020;33:51-64.e9.","DOI":"10.1016\/j.cmet.2020.10.012"},{"key":"8864_CR14","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.7150\/ijbs.65555","volume":"18","author":"M Luo","year":"2022","unstructured":"Luo M, Fu A, Wu R, Wei N, Song K, Lim S, et al. High Expression of G6PD Increases Doxorubicin resistance in triple negative breast cancer cells by maintaining GSH level. Int J Biol Sci. 2022;18:1120\u201333.","journal-title":"Int J Biol Sci"},{"key":"8864_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2023.100949","volume":"46","author":"M Winter","year":"2023","unstructured":"Winter M, Nait Eldjoudi A, Guette C, Hondermarck H, Bourette RP, Fovez Q, et al. Mitochondrial adaptation decreases drug sensitivity of persistent triple negative breast cancer cells surviving combinatory and sequential chemotherapy. Neoplasia. 2023;46:100949.","journal-title":"Neoplasia"},{"key":"8864_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07505-2","volume":"9","author":"CM Rice","year":"2018","unstructured":"Rice CM, Davies LC, Subleski JJ, Maio N, Gonzalez-Cotto M, Andrews C, et al. Tumour-elicited neutrophils engage mitochondrial metabolism to circumvent nutrient limitations and maintain immune suppression. Nat Commun. 2018;9:5099.","journal-title":"Nat Commun"},{"key":"8864_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40022-5","volume":"14","author":"R El-Botty","year":"2023","unstructured":"El-Botty R, Morriset L, Montaudon E, Tariq Z, Schnitzler A, Bacci M, et al. Oxidative phosphorylation is a metabolic vulnerability of endocrine therapy and palbociclib resistant metastatic breast cancers. Nat Commun. 2023;14:4221.","journal-title":"Nat Commun"},{"key":"8864_CR18","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1158\/0008-5472.CAN-23-0184","volume":"84","author":"S Ahn","year":"2024","unstructured":"Ahn S, Park JH, Grimm SL, Piyarathna DWB, Samanta T, Putluri V, et al. Metabolomic rewiring promotes endocrine therapy resistance in breast cancer. Cancer Res. 2024;84:291\u2013304.","journal-title":"Cancer Res"},{"key":"8864_CR19","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1158\/0008-5472.CAN-24-1204","volume":"85","author":"S Tau","year":"2025","unstructured":"Tau S, Chamberlin MD, Yang H, Marotti JD, Muskus PC, Roberts AM, et al. Oxidative phosphorylation is a metabolic vulnerability of endocrine therapy-tolerant persister cells in ER+ breast cancer. Cancer Res. 2025;85:1145\u201361.","journal-title":"Cancer Res"},{"key":"8864_CR20","doi-asserted-by":"publisher","first-page":"2970","DOI":"10.1158\/1078-0432.CCR-20-3913","volume":"27","author":"DF Boreel","year":"2021","unstructured":"Boreel DF, Span PN, Heskamp S, Adema GJ, Bussink J. Targeting oxidative phosphorylation to increase the efficacy of radio- and immune-combination therapy. Clin Cancer Res. 2021;27:2970\u20138.","journal-title":"Clin Cancer Res"},{"key":"8864_CR21","doi-asserted-by":"publisher","first-page":"11737","DOI":"10.1074\/jbc.273.19.11737","volume":"273","author":"PJ Cowan","year":"1998","unstructured":"Cowan PJ, Tsang D, Pedic CM, Abbott LR, Shinkel TA, d\u2019Apice AJ, et al. The human ICAM-2 promoter is endothelial cell-specific in vitro and in vivo and contains critical Sp1 and GATA binding sites. J Biol Chem. 1998;273:11737\u201344.","journal-title":"J Biol Chem"},{"key":"8864_CR22","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1038\/s41388-023-02769-5","volume":"42","author":"JK Pan","year":"2023","unstructured":"Pan JK, Lin WD, Kuo YL, Chen YC, Loh ZJ, Lin FC, et al. ICAM2 initiates trans-blood-CSF barrier migration and stemness properties in leptomeningeal metastasis of triple-negative breast cancer. Oncogene. 2023;42:2919\u201331.","journal-title":"Oncogene"},{"key":"8864_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/1478-811X-12-12","volume":"12","author":"V Amsellem","year":"2014","unstructured":"Amsellem V, Dryden NH, Martinelli R, Gavins F, Almagro LO, Birdsey GM, et al. ICAM-2 regulates vascular permeability and N-cadherin localization through ezrin-radixin-moesin (ERM) proteins and Rac-1 signalling. Cell Commun Signal. 2014;12:12.","journal-title":"Cell Commun Signal"},{"key":"8864_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217179","volume":"600","author":"B Liu","year":"2024","unstructured":"Liu B, Liu Y, Yang S, Ye J, Hu J, Chen S, et al. Enhanced desmosome assembly driven by acquired high-level desmoglein-2 promotes phenotypic plasticity and endocrine resistance in ER+ breast cancer. Cancer Lett. 2024;600:217179.","journal-title":"Cancer Lett"},{"key":"8864_CR25","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s41580-022-00491-w","volume":"23","author":"SE Cason","year":"2022","unstructured":"Cason SE, Holzbaur ELF. Selective motor activation in organelle transport along axons. Nat Rev Mol Cell Biol. 2022;23:699\u2013714.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"8864_CR26","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1158\/1078-0432.CCR-24-3296","volume":"31","author":"APM Beerkens","year":"2025","unstructured":"Beerkens APM, Heskamp S, Reinema FV, Adema GJ, Span PN, Bussink J. Mitochondria targeting of oxidative phosphorylation inhibitors to alleviate hypoxia and enhance anticancer treatment efficacy. Clin Cancer Res. 2025;31:1186\u201393.","journal-title":"Clin Cancer Res"},{"key":"8864_CR27","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1053\/j.gastro.2010.10.009","volume":"140","author":"N Hiraoka","year":"2011","unstructured":"Hiraoka N, Yamazaki-Itoh R, Ino Y, Mizuguchi Y, Yamada T, Hirohashi S, et al. CXCL17 and ICAM2 are associated with a potential anti-tumor immune response in early intraepithelial stages of human pancreatic carcinogenesis. Gastroenterology. 2011;140:310\u201321.","journal-title":"Gastroenterology"},{"key":"8864_CR28","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1038\/onc.2014.87","volume":"34","author":"JM Feduska","year":"2014","unstructured":"Feduska JM, Aller SG, Garcia PL, Cramer SL, Council LN, van Waardenburg RCAM, et al. ICAM-2 confers a non-metastatic phenotype in neuroblastoma cells by interaction with \u03b1-actinin. Oncogene. 2014;34:1553\u201362.","journal-title":"Oncogene"},{"key":"8864_CR29","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1083\/jcb.140.4.885","volume":"140","author":"S Yonemura","year":"1998","unstructured":"Yonemura S, Hirao M, Doi Y, Takahashi N, Kondo T, Tsukita S, et al. Ezrin\/radixin\/moesin (ERM) proteins bind to a positively charged amino acid cluster in the juxta-membrane cytoplasmic domain of CD44, CD43, and ICAM-2. J Cell Biol. 1998;140:885\u201395.","journal-title":"J Cell Biol"},{"key":"8864_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30431-3","volume":"13","author":"P Shi","year":"2022","unstructured":"Shi P, Ren X, Meng J, Kang C, Wu Y, Rong Y, et al. Mechanical instability generated by Myosin 19 contributes to mitochondria cristae architecture and OXPHOS. Nat Commun. 2022;13:2673.","journal-title":"Nat Commun"},{"key":"8864_CR31","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1038\/s42255-025-01218-9","volume":"7","author":"J Li","year":"2025","unstructured":"Li J, Huang K, Thakur M, McBride F, Sadagopan A, Gallant DS, et al. Oncogenic TFE3 fusions drive OXPHOS and confer metabolic vulnerabilities in translocation renal cell carcinoma. Nat Metab. 2025;7:478\u201392.","journal-title":"Nat Metab"},{"key":"8864_CR32","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41591-022-02103-8","volume":"29","author":"TA Yap","year":"2023","unstructured":"Yap TA, Daver N, Mahendra M, Zhang J, Kamiya-Matsuoka C, Meric-Bernstam F, et al. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nat Med. 2023;29:115\u201326.","journal-title":"Nat Med"},{"key":"8864_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1031487","volume":"13","author":"X Sun","year":"2022","unstructured":"Sun X, Tang F, Guo Q, Liu Y, He Y, Du Y, et al. HAS2-Ezrin-ER axis plays a role in acquired antiestrogen resistance of ER-positive breast cancer. Front Pharm. 2022;13:1031487.","journal-title":"Front Pharm"},{"key":"8864_CR34","doi-asserted-by":"crossref","unstructured":"Wang H, Li N, Liu Q, Guo J, Pan Q, Cheng B, et al. Antiandrogen treatment induces stromal cell reprogramming to promote castration resistance in prostate cancer. Cancer Cell 2023;41:1345-62.e9.","DOI":"10.1016\/j.ccell.2023.05.016"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08864-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08864-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08864-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:24:17Z","timestamp":1783635857000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08864-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8864"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08864-1","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]},"assertion":[{"value":"10 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The animal experiments were approved by the Institutional Animal Care and Use Committee of Jiao Tong University Affiliated Sixth People\u2019s Hospital (No.2022-0356; No:2024-0394). All methods involving animal study were performed in accordance with the relevant guidelines and regulations. Breast cancer tissues microarray was procured from Shanghai Outdo Biotech Company, and 18 human luminal-like breast cancer samples were collected from Shanghai Jiao Tong University Affiliated Sixth People\u2019s Hospital. These experiments were ethically approved by the Ethics Committee in accordance with the principles of the Helsinki Declaration. All participating patients provided written informed consent (SHYJS-CP-1701014\uff1b2022-YS-137).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have agreed to publish this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"631"}}